Home » Topics » BioWorld Science

BioWorld Science
RSS

Addressing glioblastoma by targeting LDLR with VH-DO-33 radioisotopes

July 1, 2019

[18F]Afatinib PET/CT as promising new tool for selecting patients with NSCLC for afatinib therapy

July 1, 2019

Notch1 as a promising new therapeutic target in multiple myeloma

July 1, 2019

Phase II results presented for pazopanib in patients with progressive carcinoid tumors

July 1, 2019

MolMed suspends enrollment of new patients in phase III TK008 study of Zalmoxis

July 1, 2019

ImmusanT discontinues phase II study of Nexvax2 in celiac disease

July 1, 2019

Bayer initiates phase II AVANTI study of BAY-1753011 in congestive heart failure

July 1, 2019

AptaTargets initiates first-in-human trial of ApTOLL

July 1, 2019

BR-11257, a novel nonstabilizing soluble guanylyl cyclase partial agonist

July 1, 2019

A novel androgen receptor antagonist is a promising candidate for enzalutamide-resistant CRPC

July 1, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...